[go: up one dir, main page]

WO2010115593A3 - Novel targets for the diagnosis and treatment of dysplasia - Google Patents

Novel targets for the diagnosis and treatment of dysplasia Download PDF

Info

Publication number
WO2010115593A3
WO2010115593A3 PCT/EP2010/002130 EP2010002130W WO2010115593A3 WO 2010115593 A3 WO2010115593 A3 WO 2010115593A3 EP 2010002130 W EP2010002130 W EP 2010002130W WO 2010115593 A3 WO2010115593 A3 WO 2010115593A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
gene
expression profile
gene expression
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/002130
Other languages
French (fr)
Other versions
WO2010115593A2 (en
Inventor
Jϋrgen BORLAK
Astrid Rohrbeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Original Assignee
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV filed Critical Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Publication of WO2010115593A2 publication Critical patent/WO2010115593A2/en
Publication of WO2010115593A3 publication Critical patent/WO2010115593A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

An identification of patients at risk for developing cancer at early stages of disease would have a big impact on overall survival. The molecular perturbations associated with early stages of lung cancer are, however, unknown as are the gene regulatory networks forcing dysplastic cells into malignant transformation. To this end, the invention provides a method for identifying targets for the use in diagnosis or treatment monitoring of dysplasia, comprising the steps of : laser microdissection of cells from the tissue of a transgenic animal overexpressing an oncogene placed under the control of a regulatory sequence from a tissue specific gene, wherein dysplastic cells and morphologically unaltered cells are harvested, isolating RNA (1) from the dysplatic cells and isolating RNA (2) from the morphologically unaltered cells, determining, for each of the isolated RNA (1 ) and (2), a preferably genome wide gene expression profile, and - identifying the target as a gene being significantly overexpressed in the gene expression profile of the isolated RNA (1) in comparison with the gene expression profile of the isolated RNA (2).
PCT/EP2010/002130 2009-04-03 2010-03-29 Novel targets for the diagnosis and treatment of dysplasia Ceased WO2010115593A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09075165.2 2009-04-03
EP09075165 2009-04-03

Publications (2)

Publication Number Publication Date
WO2010115593A2 WO2010115593A2 (en) 2010-10-14
WO2010115593A3 true WO2010115593A3 (en) 2010-12-16

Family

ID=42238601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/002130 Ceased WO2010115593A2 (en) 2009-04-03 2010-03-29 Novel targets for the diagnosis and treatment of dysplasia

Country Status (1)

Country Link
WO (1) WO2010115593A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336171A1 (en) * 2009-12-11 2011-06-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel targets for the treatment of proliferative diseases
KR102356955B1 (en) 2013-04-22 2022-01-28 가부시키가이샤 토치기 린쇼뵤리켄큐조 Antitumor agent
CN107267518B (en) * 2017-08-01 2019-11-26 浙江大学 The siRNA and its recombinant vector of specificity inhibition CLDN8 gene expression and application
WO2019035075A1 (en) * 2017-08-17 2019-02-21 NantOmics, LLC. Dynamic changes in circulating free rna of neural tumors
CN113122626B (en) * 2019-12-30 2023-08-11 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） Application of KLC3 Gene as a Marker in the Diagnosis and Treatment of Ovarian Cancer
CN119742082B (en) * 2025-03-04 2025-05-23 天津市胸科医院 Aortic dissection postoperative control model construction method and system based on big data

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CUNNINGHAM STEVEN C ET AL: "Claudin-4, mitogen-activated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, PHILADELPHIA, PA, US LNKD- DOI:10.1158/1055-9965.EPI-05-0539, vol. 15, no. 2, 1 February 2006 (2006-02-01), pages 281 - 287, XP009135183, ISSN: 1055-9965 *
ILONA LINNOILA R ET AL: "MORPHOMETRIC ANALYSIS OF CC10-hASH1 TRANSGENIC MOUSE LUNG: A Model for Bronchiolization of Alveoli and Neuroendocrine Carcinoma", EXPERIMENTAL LUNG RESEARCH,, vol. 26, no. 8, 1 December 2000 (2000-12-01), pages 595 - 625, XP009135031, ISSN: 0190-2148 *
KWON B S ET AL: "Isolation and sequence analysis of serine protease cDNAs from mouse cytolytic T lymphocytes", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 168, no. 5, 1 November 1988 (1988-11-01), pages 1839 - 1854, XP009135421, ISSN: 0022-1007 *
LECHNER S ET AL: "Gene expression pattern of laser microdissected colonic crypts of adenomas with low grade dysplasia", GUT, BRITISH MEDICAL ASSOCIATION, LONDON, UK LNKD- DOI:10.1136/GUT.52.8.1148, vol. 52, no. 8, 1 August 2003 (2003-08-01), pages 1148 - 1153, XP009135028, ISSN: 0017-5749 *
NAMBIAR PRASHANT R ET AL: "Genetic signatures of high- and low-risk aberrant crypt foci in a mouse model of sporadic colon cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US LNKD- DOI:10.1158/0008-5472.CAN-04-0933, vol. 64, no. 18, 15 September 2004 (2004-09-15), pages 6394 - 6401, XP002510625, ISSN: 0008-5472 *
SABATES-BELLVER JACOB ET AL: "Transcriptome profile of human colorectal adenomas", MOLECULAR CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH (A AC R), US, vol. 5, no. 12, 1 December 2007 (2007-12-01), pages 1263 - 1275, XP009135103, ISSN: 1541-7786 *
SYDER ANDREW J ET AL: "A transgenic mouse model of metastatic carcinoma involving transdifferentiation of a gastric epithelial lineage progenitor to a neuroendocrine phenotype", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US LNKD- DOI:10.1073/PNAS.0307983101, vol. 101, no. 13, 30 March 2004 (2004-03-30), pages 4471 - 4476, XP009135029, ISSN: 0027-8424 *
WAGENAAR GERRY T M ET AL: "Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress", FREE RADICAL BIOLOGY AND MEDICINE, ELSEVIER SCIENCE, US, vol. 36, no. 6, 15 March 2004 (2004-03-15), pages 782 - 801, XP009135196, ISSN: 0891-5849 *
WALCH AXEL ET AL: "Microdissection of tissue sections: Application to the molecular genetic characterisation of premalignant lesions", PATHOBIOLOGY, KARGER, BASEL, CH LNKD- DOI:10.1159/000028110, vol. 68, no. 1, 1 January 2000 (2000-01-01), pages 9 - 17, XP002188837, ISSN: 1015-2008 *

Also Published As

Publication number Publication date
WO2010115593A2 (en) 2010-10-14

Similar Documents

Publication Publication Date Title
Johnson et al. Computational identification of MiRNA-7110 from pulmonary arterial hypertension (PAH) ESTs: a new microRNA that links diabetes and PAH
WO2010115593A3 (en) Novel targets for the diagnosis and treatment of dysplasia
WO2007140958A3 (en) Method for identifying whether a patient will be responder or not to immunotherapy
EP4180531A3 (en) Nasal epithelium gene expression signature and classifier for the prediction of lung cancer
WO2009072610A1 (en) Cancer vaccine composition
Branco et al. Systemic signalling through translationally controlled tumour protein controls lateral root formation in Arabidopsis
WO2011133609A3 (en) Methods and kits to predict therapeutic outcome of btk inhibitors
WO2011091389A3 (en) Cyclovirus and method of use
WO2008107114A3 (en) Control genes for the normalization of gene expression analysis data
WO2018212361A8 (en) Method of treating diseases associated with myd88 pathways using crispr-gndm system
Nageshan et al. Post-transcriptional repair of a split heat shock protein 90 gene by mRNA trans-splicing
Shah et al. miRNA 21: diagnostic prognostic and therapeutic marker for oral cancer
DE602006012995D1 (en) BREAST CANCER DIAGNOSTIC PROCEDURE
Sun et al. Krüppel‐Like Factor 4 Inhibits the Transforming Growth Factor‐β1‐Promoted Epithelial‐to‐Mesenchymal Transition via Downregulating Plasminogen Activator Inhibitor‐1 in Lung Epithelial Cells
WO2015121737A3 (en) Transcriptomic biomarkers, method for determination thereof and use of trnascriptomic biomarkers for individual risk assessment of developing post-infraction heart failure
CN106048073B (en) Biomarker and its application of a kind of oophoroma auxiliary diagnosis or outcome prediction
WO2013093353A3 (en) Method for the diagnosis or prognosis, in vitro, of lung cancer
CN106319043B (en) The application method of long-chain non-coding RNA LINC01420
EP2576816A4 (en) METHOD AND KIT FOR DISCRIMINATION BETWEEN BREAST CANCER AND BENIGN BREAST DISEASE
Li et al. Aberrant expression of TNRC6a and miR-21 during myocardial infarction
CN101671669B (en) A liver cancer targeting gene expression element AE and its application
US20160152977A1 (en) Analyzing method for micro rna id and biomarkers related to colon cancer through this method
Bourgo et al. RB deletion disrupts coordination between DNA replication licensing and mitotic entry in vivo
CN107460192B (en) C-Myc protein bindable DNA fragment and application thereof in c-Myc activity detection
WO2004013631A3 (en) Compositions and methods for diagnosis and therapy of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10715499

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10715499

Country of ref document: EP

Kind code of ref document: A2